What's the mechanism behind nivolumab causing skin reactions?

What triggers skin reactions with nivolumab?

Nivolumab, a checkpoint inhibitor used in cancer treatment, can cause a range of skin reactions. The primary mechanism behind these reactions is the activation of T-cell response [1]. Nivolumab works by blocking the PD-1 receptor, a protein on T-cells that typically inhibits immune responses. This blockade allows T-cells to attack cancer cells more effectively.

Why do T-cells trigger skin reactions?

In addition to targeting cancer cells, the activated T-cells can also recognize and attack healthy cells, leading to skin reactions [2]. The skin is a common site of immune system activity, and the T-cells responding to nivolumab can cause inflammation, leading to conditions like rash, itching, and dryness.

Types of skin reactions caused by nivolumab

The most common skin reactions associated with nivolumab include:

* Rash: a red, itchy patch on the skin that can be painful
* Itching: a general sensation of discomfort or tingling in the skin
* Dry skin: a condition characterized by dry, flaky, or scaly skin

These reactions are typically mild to moderate in severity and usually resolve on their own within a few weeks [3]. However, in some cases, skin reactions can be more severe and may require medical attention.

Predicting and managing skin reactions

Predicting individual responses to nivolumab is challenging, but patients at higher risk for skin reactions tend to have pre-existing autoimmune diseases or a history of severe reactions to other checkpoint inhibitors [4]. To manage skin reactions, patients should inform their healthcare provider about any changes in their skin or overall health.

Sources:
[1] Topalian et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine.
[2] Robert et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine.
[3] Wolchok et al. (2017). Nivolumab versus ipilimumab in patients with treatment-naive advanced melanoma: 2-year outcomes from a randomised, double-blind, phase 2 trial (CheckMate 037). The Lancet Oncology.
[4] Schadendorf et al. (2015). Efficacy and safety of nivolumab in advanced melanoma. Journal of Clinical Oncology.

External source:
www.drugpatentwatch.com